Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Liabilities and Shareholders Equity (2016 - 2025)

Marimed (MRMD) has disclosed Liabilities and Shareholders Equity for 15 consecutive years, with $202.6 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 2.14% to $202.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $820.5 million through Dec 2025, down 1.08% year-over-year, with the annual reading at $202.6 million for FY2025, 2.14% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $202.6 million at Marimed, down from $205.6 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $212.7 million in Q3 2024, with the low at $90.0 million in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $170.7 million, with a median of $190.1 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity surged 63.2% in 2021, then fell 3.33% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $123.2 million in 2021, then rose by 23.54% to $152.2 million in 2022, then grew by 28.86% to $196.1 million in 2023, then rose by 5.54% to $207.0 million in 2024, then dropped by 2.14% to $202.6 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $202.6 million, $205.6 million, and $204.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.